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Abstract Limited data exist regarding treatment pat-
terns and outcomes in elderly patients with HER2-positive
metastatic breast cancer (MBC). registHER is an obser-
vational study of patients (N = 1,001) with HER2-positive
MBC diagnosed within 6 months of enrollment and fol-
lowed until death, disenrollment, or June 2009 (median
follow-up 27 months). Outcomes were analyzed by age at
MBC diagnosis: younger (\65 years), older (65–74 years),
elderly (C75 years). For progression-free survival (PFS)
and overall survival (OS) analyses of first-line trastuzumab
versus nontrastuzumab, older and elderly patients were
combined. Cox regression analyses were adjusted for
baseline characteristics and treatments. Estrogen receptor/
progesterone receptor status was similar across age groups.
Underlying cardiovascular disease was most common in
elderly patients. In patients receiving trastuzumab-based
first-line treatment, elderly patients were less likely to
receive chemotherapy. In trastuzumab-treated patients,
incidence of left ventricular dysfunction (LVD) and con-
gestive heart failure (CHF) (grades C 3) were highest in
elderly patients (LVD: elderly 4.8 %, younger 2.8 %, older
1.5 %; CHF: elderly 3.2 %, younger 1.9 %, older 1.5 %).
Unadjusted median PFS (months) was significantly higher
in patients treated with first-line trastuzumab than those
who were not (\65 years: 11.0 vs. 3.4, respectively;
C65 years: 11.7 vs. 4.8, respectively). In patients
\65 years, unadjusted median OS (months) was signifi-
cantly higher in trastuzumab-treated patients; in patients
C65 years, median OS was similar (\65 years: 40.4 vs.
25.9; C65 years: 31.2 vs. 28.5). In multivariate analyses,
first-line trastuzumab use was associated with significant
improvement in PFS across age. For OS, signifi-
cant improvement was observed for patients \65 years
and nonsignificant improvement for patients C65 years.
Elderly patients with HER2-positive MBC had higher rates
of underlying cardiovascular disease than their younger
counterparts and received less aggressive treatment,
including less first-line trastuzumab. These real-world data
suggest improved PFS across all age groups and similar
trends for OS.
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Abbreviations
BMI Body mass index
CHF Congestive heart failure
CVD Cardiovascular disease
CNS Central nervous system
ECOG Eastern Cooperative Oncology Group
ER Estrogen receptor
FDA Federal Drug Administration
HR Hormone receptor
MI Myocardial infarction
LVD Left ventricular dysfunction
MBC Metastatic breast cancer
PFS Progression-free survival
PR Progesterone receptor
OS Overall survival
Introduction
In the US, breast cancer is the most common cause of cancer-
related deaths in women aged C65 years [1–3], and the
average age at diagnosis is approximately 63 years [3]. In the
2000–2008 Surveillance, Epidemiology, and End Results
(SEER) database, nearly 50 % of breast cancer cases
occurred in women aged C65 years, and 47 % occurred in
women aged C70 years [4]. Despite the high incidence and
mortality of breast cancer in older women, knowledge about
aging and breast cancer and about optimal treatment for older
cancer patients is inadequate, mostly due to the underrep-
resentation of these patients in prospective clinical trials [5].
Cancer patients age 70 or greater comprised only 20 % of
subjects enrolled in US Food and Drug Administration
(FDA) registration trials from 1995 to 1999, though they
made up fully 46 % of the US cancer population [6].
Elderly breast cancer patients are often underrepresented
in clinical trials because of higher rates of underlying
comorbidities, concerns about toxicity of therapies,
including cardiotoxicity, risks of mortality, and other rea-
sons [7–9]. Elderly patients are also underrepresented in
clinical trials due to ‘‘physician bias,’’ based on the concern
that a patient will not tolerate or benefit from treatment,
and ‘‘patient and family member bias,’’ based on the belief
that the treatment may not be worthwhile or too toxic [4].
Because of the scarcity of randomized trials which include
elderly patients, there is little evidenced-based data on
treatment-related outcomes in this patient population [10],
yet available studies indicate that older women are less
likely to receive standard therapy for their breast cancer
[7, 10–13]. In a review of 407 breast cancer patients aged
C80 years, Bouchardy et al. [14] reported that half were
undertreated, with significantly decreased survival in this
cohort as a consequence.
HER2-positive breast cancer, which comprises 20–25 %
of breast cancer, is associated with poor prognosis and is a
significant adverse predictor of both overall survival (OS)
and time to relapse [15–17]. We examined a large cohort of
elderly patients with HER2-positive metastatic breast
cancer (MBC) to date in terms of demographic and clinical
characteristics, treatment patterns, and safety and efficacy
outcomes in the registHER observational study. This pop-
ulation registry provides a unique opportunity to gain
important insights and valuable benchmarks to guide
clinical management of these patients.
Methods
Study design and patients
registHER is a prospective, multicenter, observational US-
based cohort study of 1,023 patients (n = 1,013 women
and n = 10 men) recruited from community and academic
settings between December 2003 and February 2006. The
objectives of the registHER study were to describe the
natural history of disease and treatment patterns for
patients with HER2-positive MBC, and to explore associ-
ations between demographic and clinical factors, specific
therapies, and patient outcomes.
Details regarding the registHER study design and
recruitment are described elsewhere [18]. In brief, patients
with a history of either recurrent metastatic HER2-positive
breast cancer or those presenting with an initial diagnosis
of metastatic (stage IV) breast cancer were eligible within
6 months of this diagnosis, provided that all required
cancer-specific historical data points were available in the
medical record. Patients received care according to their
physicians’ standard practice without any study-specified
therapy or evaluations. Prior or planned treatment with
trastuzumab, or any specific HER2-targeted therapy, was
not a requirement for study participation. All patients
signed an informed consent and authorization to disclose
their health information. There were no exclusion criteria
for participation in the study; however, patients who did
not consent and provide authorization of health information
disclosure were excluded.
Data collection
Data collected for enrolled patients included demographics,
height and weight, cardiac history and other significant
comorbidities, date of initial breast cancer diagnosis and
stage, histology, hormone receptor (HR) and HER2 status,
prior adjuvant or radiotherapy, and date of MBC diagnosis
with sites of metastatic disease at diagnosis.
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After enrollment, follow-up was done every 3 months
thereafter, at which time treatment history, sites of progres-
sive disease, tumor response, survival, cardiac safety (grades
3/4/5), and adverse events possibly related to the adminis-
tration of trastuzumab were collected. Cardiac safety events
were defined based on the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events, v3.0, and
selected based on physician subjective opinion [19].
Treatments for MBC were administered according to
standard-of-care by the treating oncologist. Formal, pre-
specified, and scheduled assessments for tumor response
were not required, and tumor response or progression was
reported by physicians according to their standard judg-
ment and practice.
Statistical methods
Enrollment of 83 patients whose MBC diagnosis was more
than 6 months (up to 9 months) prior to enrollment was
permitted and these patients are included in all analyses. A
total of 22 patients did not receive any treatment during the
study and were excluded. Trastuzumab-based regimens
were defined as patients receiving C21 days of trast-
uzumab in the first line. For this analysis, patients were
stratified into three groups based on age at MBC diagno-
sis: younger (\65 years), older (65–74 years), elderly
(C75 years). Demographic and clinical characteristics were
generated across each age group (younger, older, and
elderly). For progression-free survival (PFS) and OS
analyses of first-line trastuzumab versus nontrastuzumab,
older and elderly patients were combined due to the small
number of events in the elderly (\65 vs. C65). OS was
based on overall cancer-related deaths, as breast cancer-
specific mortality was not collected in registHER.
PFS and OS were analyzed using the Kaplan–Meier
method. A hierarchical modeling approach was used in the
multivariate analysis to assess the effects of age, first-line
trastuzumab use (yes vs. no), and their interaction on time
to event endpoints. The initial Cox proportional model
included only age and first-line trastuzumab use. The fol-
lowing patient baseline characteristics were subsequently
adjusted for in the multivariate models: race/ethnicity,
European Cooperative Group (ECOG) performance status,
serum albumin level, estrogen/progesterone receptor (ER/
PR) status, site of metastatic disease, number of metastatic
sites, stage of disease at initial diagnosis, history of
underlying cardiovascular disease (CVD), and history of
other underlying noncardiac comorbidities. The final mul-
tivariate models further adjusted for patient first-line
treatment variables, such as receiving first-line chemo-
therapy and first-line hormonal therapy. All models were
fitted with and without age and first-line trastuzumab use
interaction terms.
Results
Patient baseline and clinical characteristics
Table 1 shows baseline demographic and clinical charac-
teristics for the 1,001 patients who were followed until death,
disenrollment, or the June 2009 data lock (median follow-up
was 27 months). The median age of younger (\65 years)
patients was 50 years, for older (65–74 years) patients it was
69 years, and for elderly (C75 years) patients it was
79 years. The great majority of patients in each age group
were female (99–100 %). Elderly (C75 years) patients were
more likely to be white and less likely to be obese (body mass
index C30 kg/m2) compared with younger and older
patients. Most patients had ECOG status of 0–1 at diagnosis.
Distribution of site of metastatic disease at diagnosis of
MBC showed central nervous system (CNS) and visceral
metastases were less common in elderly patients compared
with the other age groups, whereas metastases to bone or
bone plus breast and node/local sites at diagnosis were
more common in elderly patients. Also, elderly patients
were most likely to have had clinical stage I–III disease at
the time of initial diagnosis with a disease-free interval of
[12 months (72.3 %), compared with younger (57.7 %)
and older patients (61.1 %). Elderly patients were also least
likely to have had initial diagnosis of early stage disease
with disease-free interval of B12 months (6.2 %) com-
pared with younger (13.6 %) and older (16.0 %) patients.
ER/PR status was similar across age groups, and approxi-
mately half of patients in all groups were ER/PR-positive.
Elderly patients were also most likely to have a history of
diabetes (16.9 %) compared with younger (5.9 %) and older
(14.6 %) patients. In addition, at baseline, elderly patients
had a higher rate of underlying CVD, with 46.2 % reporting
some type of CVD at baseline compared with 29.2 % in older
and 12.6 % in younger patients. Elderly patients were most
likely to report arrhythmia, hypertension with complica-
tions, congestive heart failure (CHF), myocardial infarction,
and ‘‘other’’ underlying cardiac diseases.
Treatment patterns prior to first disease progression
First-line treatment patterns are based on treatment received
after diagnosis of metastatic disease and prior to first disease
progression and may have been given sequentially or con-
currently. Elderly patients were least likely to receive trast-
uzumab-based first-line treatment (77 %, 50/65) compared
with older patients (81 %, 117/144) and younger patients
(85 %, 674/792), although these differences were modest.
Among patients receiving trastuzumab-based first-line
treatment, elderly patients were least likely to receive che-
motherapy plus trastuzumab and most likely to receive
trastuzumab alone or combined with hormonal therapy
Breast Cancer Res Treat (2012) 135:875–883 877
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compared with younger and older patients (Table 2). Among
patients receiving nontrastuzumab-based first-line treat-
ment, elderly patients were least likely to receive chemo-
therapy only and most likely to receive hormonal therapy
only or hormonal therapy combined with chemotherapy
compared with the other age groups.
Cardiac safety outcomes
Table 3 shows the incidence of cardiac adverse events
(grades C 3) for all patients treated with trastuzumab. In the
63 elderly patients included in the analysis, the incidence of
any cardiac adverse event was 25.4 %, compared with
6.8 % in younger and 6.7 % in older patients. The incidence
of left ventricular dysfunction (LVD) was highest in elderly
patients (4.8 %) compared with younger (2.8 %) and older
patients (1.5 %). The incidence of CHF was also highest in
elderly patients (3.2 %) compared with younger (1.9 %)
and older patients (1.5 %). When stratified by underlying
disease history, elderly patients with a history of hyper-
tension with complications or any CVD were more likely to
have cardiac safety events and compromise of left ventricle
function compared with younger or older patients. Specifi-
cally, of the elderly patients reporting hypertension with
Table 1 Baseline demographic
and clinical characteristics of
younger (\65 years), older
(65–74 years), and elderly
(C75 years) patients at
diagnosis of MBC
BMI body mass index, CNS
central nervous system, CVD
cardiovascular disease, MBC
metastatic breast cancer, ECOG
Eastern Cooperative Oncology
Group, ER estrogen receptor,
PR progesterone receptor
a Patients could be counted in
multiple CVD categories
Variable, n (%) Age (years) at MBC
\65
(n = 792)
65–74
(n = 144)
C75
(n = 65)
Age at enrollment (years), median (range) 50 (20–65) 69 (65–75) 79 (75–92)
Race/ethnicity
White 614 (77.5) 123 (85.4) 56 (86.2)
Black 106 (13.4) 14 (9.7) 6 (9.2)
Other 72 (9.1) 7 (4.9) 3 (4.6)
BMI, kg/m2
\30 506 (63.9) 91 (63.2) 53 (81.5)
C30 286 (36.1) 53 (36.8) 12 (18.5)
ECOG performance status at diagnosis
0–1 361 (45.6) 69 (47.9) 25 (38.5)
2? 44 (5.6) 11 (7.6) 5 (7.7)
Unknown/missing 387 (48.9) 64 (44.4) 35 (53.8)
Site of metastatic disease at diagnosis
Any CNS 63 (8.0) 8 (5.6) 1 (1.5)
Bone only or bone ? breast 118 (14.9) 18 (12.5) 12 (18.5)
Visceral 478 (60.4) 92 (63.9) 37 (56.9)
Node/local 131 (16.5) 26 (18.1) 15 (23.1)
Other sites 2 (0.3) 0 (0) 0 (0)
Clinical stage at initial diagnosis
Stage I–III, MBC B12 months after initial diagnosis 108 (13.6) 23 (16.0) 4 (6.2)
Stage I–III, MBC[12 months after initial diagnosis 457 (57.7) 88 (61.1) 47 (72.3)
Stage IV 227 (28.7) 33 (22.9) 14 (21.5)
ER/PR status
ER? or PR? 426 (53.8) 71 (49.3) 33 (50.8)
ER- and PR- 341 (43.1) 63 (43.8) 30 (46.2)
Unknown 25 (3.2) 10 (6.9) 2 (3.1)
History of diabetes 46 (5.9) 21 (14.6) 11 (16.9)
History of underlying CVDa 100 (12.6) 42 (29.2) 30 (46.2)
Arrhythmia 7 (0.9) 7 (4.9) 8 (12.3)
Congestive heart failure 6 (0.8) 3 (2.1) 6 (9.2)
Hypertension with complications 21 (2.7) 18 (12.5) 9 (13.8)
Angina 2 (0.3) 0 (0.0) 1 (1.5)
Myocardial infarction 9 (1.1) 5 (3.5) 5 (7.7)
Peripheral vascular disease 8 (1.0) 3 (2.1) 2 (3.1)
Other underlying cardiac disease 61 (7.7) 21 (14.6) 17 (26.2)
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complications (n = 8), 25.0 % (n = 2) had any cardiac
safety event and 25.0 % (n = 2) had LVD compared with
younger patients (0 % for either cardiac or LVD) and older
patients [11.1 % (n = 2) for cardiac, 0 % for LVD]. Sim-
ilarly, of the elderly patients reporting underlying cardio-
vascular disease (n = 27), 33.3 % (n = 9) had a cardiac
safety event and 11.1 % (n = 3) had an LVD event com-
pared with younger patients [5.3 % (n = 5) for cardiac, 0 %
for LVD] and older patients [7.7 % (n = 3) for cardiac, 0 %
for LVD]. Due to the small number of safety events, these
associations were not statistically significant.
Rates of cancer-related deaths were similar across age
groups: (81.4 %, 35/43) in elderly patients, (82.4 %, 70/85)
in older patients, and (89.5 %, 367/410) in younger
patients.
Survival outcomes based on trastuzumab treatment
For PFS and OS analyses of first-line trastuzumab versus
nontrastuzumab, older and elderly patients were combined
due to the small number of events in the elderly. For patients
aged \65 years, unadjusted median PFS was significantly
greater for patients treated with first-line trastuzumab versus
patients not treated with first-line trastuzumab (11.0 vs.
3.4 months); in patients C65 years, PFS was also signifi-
cantly higher in trastuzumab-treated patients (11.7 vs.
4.6 months) (Fig. 1, panels a, b). In patients aged\65 years,
unadjusted median OS was significantly higher in trast-
uzumab-treated patients (40.4 months trastuzumab vs.
25.9 months nontrastuzumab); in patients C65 years, med-
ian OS was similar in both the treatment groups
(31.2 months trastuzumab vs. 28.5 months nontrastuzumab)
(Fig. 1, panels c, d).
In multivariate analyses (Table 4), trastuzumab used
in first-line therapy was associated with significant
improvement in PFS across age groups. For OS, significant
improvement was observed for patients \65 years; a non-
significant improvement for patients C65 years was
observed. Age and first-line trastuzumab use interaction
terms were not statistically significant (data not shown).
Clinical outcomes
Among all treated patients with disease progression, rates
of CNS metastasis were lowest in the elderly (9.3 %)
compared with younger (22.3 %) and older (16.8 %)
patients (Fig. 2). Rates of first disease progression to vis-
ceral, node/locoregional, and other sites were the same or
increased in elderly patients compared with other age
groups, while rates were lower for bone only or bone and
breast for the elderly patients compared with younger.
Discussion
There continues to be a paucity of data characterizing
elderly breast cancer patients. With the increasingly older
world population, oncologists are faced with an imposing
challenge due to the growing cancer burden and the spe-
cific health care needs of older cancer patients [10, 20].
With the largest cohort of HER2-positive elderly breast
cancer patients to date, the registHER study allows the
unique and important opportunity to examine the natural
history of disease and treatment patterns in these patients.
Elderly patients had higher rates of underlying CVD and
were less likely to be treated with cytotoxic therapies
compared with their younger counterparts. While there was
an increased incidence of CVD events in the elderly during
follow-up, there was evidence of an association with
comorbidities, including hypertension with complications
Table 2 First-line treatment
patterns in younger (\65 years),
older (65–74 years), and elderly
(C65 years) patients in
registHER
a Trastuzumab-based regimens
defined as patients receiving
C21 days of trastuzumab in
first-line; n = 11 patients
received trastuzumab for
\21 days in first-line and were
not included
Treatment Age (years) at MBC diagnosis
\65 65–74 C75
(n = 674) (n = 117) (n = 50)
Trastuzumab-based first-line regimensa
With chemotherapy only 453 (67.2) 82 (70.1) 30 (60.0)
With hormonal therapy only 36 (5.3) 5 (4.3) 9 (18.0)
With chemotherapy & hormonal therapy 145 (21.5) 16 (13.7) 4 (8.0)
Trastuzumab alone 40 (5.9) 14 (12.0) 7 (14.0)
(n = 118) (n = 27) (n = 15)
Nontrastuzumab-based regimens
Chemotherapy only 62 (52.5) 12 (44.4) 5 (33.3)
Hormonal therapy only 37 (31.4) 13 (48.1) 8 (53.3)
Chemotherapy and hormonal therapy 8 (6.8) 2 (7.4) 2 (13.3)
Untreated 11 (9.3) 0 0
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and any CVD. Among treated patients with disease pro-
gression, the rate of CNS metastasis decreased with
increasing age. This observation of a decreased incidence
of CNS metastases in patients with HER2-positive MBC
with increasing age has not been appreciated previously.
Regardless of age, among patients receiving first-line
treatment with trastuzumab, PFS was higher compared
with those not treated with trastuzumab. OS was higher for
patients \65 years and similar for patients C65 years of
age.
Elderly patients (C75 years) with HER2-positive MBC
in registHER had higher rates of underlying CVD than
their younger counterparts. The increased incidence of
CVD events in elderly patients during 27 months of fol-
low-up was clinically modest (the incidences of LVD and
CHF were each below 5 %). However, a subanalysis noting
a possible association with underlying comorbidities sug-
gested a possible subset of elderly patients (those hyper-
tension with complications and any underlying CVD) at an
increased risk of CVD events, although these results are
based on small numbers. Our findings compare favorably
with a recent population-based study assessing the risk of
cardiotoxicities in association with trastuzumab with/
without anthracyclines in 47,806 women aged C65 years
with breast cancer diagnosed between 1998 and 2005 [21].
The cumulative incidence of CHF at Year 1 was 5.5 % for
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Fig. 1 Kaplan–Meier plots showing progression-free survival
(a, b) and overall survival (c, d) as diagnosis of MBC in patients
\65 and C65 years receiving trastuzumab in first-line therapy versus
nontrastuzumab in first-line therapy OS overall survival, PFS pro-
gression-free survival, T trastuzumab
Table 3 Incidence of cardiac adverse events (grades C3) in trast-
uzumab-treated younger (\65 years), older (65–74 years), and
elderly (C65 years) patients
Adverse event,
n (%)
Age (years) at MBC
\65
(n = 746)
65–74
(n = 134)
C75
(n = 63)
Any 51 (6.8) 9 (6.7) 16 (25.4)
Angina pectoris 1 (0.13) 1 (0.75) 0 (0.0)
Atrial arrhythmia 2 (0.27) 1 (0.75) 2 (3.1)
Cardiac disorder
(NOS)
8 (1.1) 2 (1.5) 4 (6.3)
Congestive heart
failure
14 (1.9) 2 (1.5) 2 (3.2)
Left ventricular
dysfunction
21 (2.8) 2 (1.5) 3 (4.8)
Myocardial infarction 1 (0.13) 1 (0.75) 2 (3.2)
Pericardial effusion 4 (0.53) 0 (0.0) 2 (3.2)
Ventricular arrhythmia 0 (0.0) 0 (0.0) 1 (1.6)
NOS not otherwise specified
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patients receiving anthracycline and trastuzumab, and
7.8 % for patients receiving trastuzumab without anthra-
cycline. Consistent with our findings, risk factors for
trastuzumab cardiotoxicity in another study included age
[50, hypertension, and baseline cardiac dysfunction [22].
In a recent retrospective study of 45 patients, trastuzumab-
treated elderly breast cancer patients (aged C 70 years)
with a history of cardiac disease and/or diabetes had an
increased incidence of cardiotoxicity [23]: the overall
incidence of cardiac events was 26.7 % (n = 12 patients),
in which 8 patients (17.8 %) developed asymptomatic left
ventricular ejection fraction decline and 4 patients (8.9 %)
developed symptomatic CHF. This incidence is higher than
that reported in the recently published Cochrane meta-
analysis of trastuzumab clinical trials [24], although this
report encompassed patients of all the age groups.
It is important to note that our follow-up period of
27 months likely captured all toxicity events in the regis-
tHER cohort. In a real-world, multicenter study of 499
consecutive patients with HER2-positive early breast can-
cer, trastuzumab cardiotoxicity most often occurred in the
first 3 months of therapy (41 % of cases), with the greatest
prevalence in older patients with higher creatinine levels
and in patients pretreated with doxorubicin and radiother-
apy [25]. These results highlight the importance of
obtaining a full medical history from patients before ini-
tiating anti-HER2 therapies to identify potential risk factors
for cardiac dysfunction.
In our study, regardless of age, PFS was significantly
higher in patients receiving first-line trastuzumab therapy
compared with patients not treated with trastuzumab; for
OS, significant improvement was observed for patients
\65 years. A nonsignificant improvement was observed
for trastuzumab-treated patients C65 years, which may be
due to the small number of events in this age group. It is
also possible that competing mortality from other causes in
the C65-year-old age group diluted the mortality benefit
from trastuzumab. These findings support those from a
recent study by Griffiths et al. [26] who used the national
SEER database to describe a large cohort (N = 610) of
older women (mean age 74 years) with HER2-positive
MBC treated with first-line or delayed trastuzumab treat-
ment. Their findings showed that OS in older women with
HER2-positive MBC treated with trastuzumab in combi-
nation with chemotherapy were similar to outcomes
reported for younger patients.
The observation of decreasing CNS metastasis with
increasing age may be due to underlying pathophysiology
or treatment effects (or both). Other evidence suggests that
older patients are less likely to develop CNS metastases. In
another study of the registHER population which included
1,012 patients who had confirmed HER2-positive tumors,
Brufsky et al. [18] found that those with CNS metastases
were younger (B65 years) and also more likely to have
HR-negative disease [18]. Similarly, in a separate study in
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Table 4 Multivariate results for PFS and OS in younger (\65 years)
and combined older and elderly (C65 years) patients (trastuzumab in
first-line vs. nontrastuzumab in first-line)
Hazard ratio 95 % CI P value**
PFS
\65 years 0.40 (0.32–0.49) \0.01
C65 years 0.52 (0.36–0.76) \0.01
OS
\65 years 0.60 (0.46–0.78) \0.01
C65 years 0.76 (0.47–1.20) 0.23
Multivariate results: adjusted for race, ECOG performance status,
serum albumin, ER/PR status, number of metastatic sites, stage, under-
lying CVD, noncardiac comorbidities, first-line chemotherapy, first-
line hormonal therapy
** For comparing patients who received versus those who did not
receive trastuzumab in first-line within age group
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2,685 primary breast cancer patients, those at increased risk
for CNS metastasis were younger and ER- or PR-;
importantly, adjuvant systemic therapies in this study were
not associated with an increase in CNS metastasis risk [27].
Indeed, as trastuzumab and most chemotherapeutic agents
do not readily cross an intact blood brain barrier [18, 28],
and as elderly patients in registHER were less likely to
receive cytotoxics, the observation of decreased CNS
metastasis in the elderly is potentially due to a combination
of both disease pathophysiology and treatment effects.
These findings warrant further research.
An inherent limitation of this study is possible ‘‘con-
founding by indication,’’ due to the nonrandomized,
observational nature of the registHER study. In observa-
tional studies, bias from confounding by indication—also
referred to as ‘‘treatment selection bias’’—may result
because selection of treatments is not random and is
determined by patient and physician characteristics; the
observed effect can, therefore, be influenced by factors
other than the treatment. There is also the potential for
residual confounding by certain clinical factors that may
not have been collected or sufficiently captured. Because
patients may have had a diagnosis of MBC up to 9 months
prior to enrollment and patients with longer survival may
be more likely to enroll, OS estimates from time of MBC
diagnosis in registHER may be slightly higher than
expected in a general MBC patient population. Finally,
limited information was collected for cause of death in
registHER (options included only ‘‘cancer’’ and ‘‘other’’)
and cause of death was missing for[5 % of deaths, which
precluded the calculation of breast cancer-specific mortal-
ity rates in this study. Our findings should also be inter-
preted with caution, due to the small number of events in
elderly patients in our study.
Conclusions
Consistent with data from prospective randomized phase
III trials [29, 30], these real-world data from the registHER
study suggest improved PFS across all age groups, with OS
benefits for the younger and older groups, and a possible
trend for OS in the elderly. While elderly patients had
higher rates of underlying CVD, they maintained a toler-
able cardiac safety profile for trastuzumab compared with
younger patients. Nonetheless, it is important that cardiac
risk factors be taken into account when making treatment
decisions, in addition to ongoing monitoring for the
emergence of such events. We report a substantial decrease
in the incidence of CNS metastases with increasing age in
elderly patients with HER2-positive MBC. The data from
this analysis of HER2-positive elderly patients will provide
oncologists with a better understanding of this patient
population and may help guide treatment in both the clinic
and the future clinical trials. Enhancing our knowledge in
treating the MBC patient is particularly crucial in the un-
dertreated elderly patient, who has a more limited life
expectancy.
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